Development of an induced pluripotent stem cell-specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products

被引:8
作者
Chung, Liam [1 ]
Cogburn, Amarin [1 ]
Sui, Lina [1 ]
Dashnau, Jennifer L. [1 ]
机构
[1] Century Therapeut Inc, Philadelphia, PA 19104 USA
关键词
cell therapy; ddPCR; drug product; iPSC; microRNA; DIGITAL PCR; T-CELLS; TRANSPLANTATION;
D O I
10.1016/j.jcyt.2022.02.005
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Most clinically evaluated chimeric antigen receptor (CAR)-based cell therapies are generated from autologous immune cells. However, there are several limitations to autologous cell therapy, including low availability, poor quality of starting cellular material and limited expansion capability. Recently, induced pluripotent stem cell (iPSC)-derived allogeneic cell therapy platforms have gained popularity, as they seek to overcome many of the challenges inherent to current autologous cell therapies. However, teratoma risk associated with residual undifferentiated cells (i.e., iPSCs) in the drug product may restrict potential clinical applications if left unaddressed. To ensure the safety of the final cell therapy product, there is a need to develop quality control assays to detect residual iPSCs. Combining microRNA (miRNA) sequencing data with publicly archived miRNA microarray datasets, we demonstrated that miRNAs belonging to the 300 family (miR-302a5p, miR-302c-3p and miR-302d-5p) and 500 family (miR-518f-5p and miR-519-3p) were highly expressed in iPSCs (both periperal blood mononuclear cell- and T cell-derived iPSCs) compared with a number of differentiated cell types. We developed and validated a sensitive digital droplet polymerase chain reaction (ddPCR) assay targeting these miRNAs to detect low levels of residual iPSCs in differentiated cell samples. The miRNA ddPCR-based method with primers for miR-302a-5p, miR-302c-3p and miR-302d-5p detected as few as 5, 3 and 10 undifferentiated iPSCs, respectively, in the background of 106 iPSC-derived natural killer (iNK) cells. These results suggest that our method targeting identified iPSC-specific miRNA transcripts is specific and sensitive for the quality assessment of NK cell therapy products derived from iPSCs. (c) 2022 Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.
引用
收藏
页码:733 / 741
页数:9
相关论文
共 47 条
  • [11] miRNA profiling during antigen-dependent T cell activation: A role for miR-132-3p
    Gutierrez-Vazquez, Cristina
    Rodriguez-Galan, Ana
    Fernandez-Alfara, Marcos
    Mittelbrunn, Maria
    Sanchez-Cabo, Fatima
    Jorge Martinez-Herrera, Dannys
    Ramirez-Huesca, Marta
    Pascual-Montano, Alberto
    Sanchez-Madrid, Francisco
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [12] Novel surface-enhanced Raman scattering-based assays for ultra-sensitive detection of human pluripotent stem cells
    Han, Jingjia
    Qian, Ximei
    Wu, Qingling
    Jha, Rajneesh
    Duan, Jinshuai
    Yang, Zhou
    Maher, Kevin O.
    Nie, Shuming
    Xu, Chunhui
    [J]. BIOMATERIALS, 2016, 105 : 66 - 76
  • [13] AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB
    Hornick, Noah I.
    Doron, Ben
    Abdelhamed, Sherif
    Huan, Jianya
    Harrington, Christina A.
    Shen, Rongkun
    Cambronne, Xiaolu A.
    Verghese, Santhosh Chakkaramakkil
    Kurre, Peter
    [J]. SCIENCE SIGNALING, 2016, 9 (444)
  • [14] ICH, 2005, ICH TOPIC Q2 R1 VALI
  • [15] Tumorigenicity assay essential for facilitating safety studies of hiPSC-derived cardiomyocytes for clinical application
    Ito, Emiko
    Miyagawa, Shigeru
    Takeda, Maki
    Kawamura, Ai
    Harada, Akima
    Iseoka, Hiroko
    Yajima, Shin
    Sougawa, Nagako
    Mochizuki-Oda, Noriko
    Yasuda, Satoshi
    Sato, Yoji
    Sawa, Yoshiki
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [16] Iwasaki K, 2013, AM J TRANSPLANT, P13
  • [17] Human microRNA targets (vol 2, pg 1862, 2005)
    John, B
    Enright, AJ
    Aravin, A
    Tuschl, T
    Sander, C
    Marks, DS
    [J]. PLOS BIOLOGY, 2005, 3 (07): : 1328 - 1328
  • [18] Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
    Junghans, Richard P.
    Ma, Qiangzhong
    Rathore, Ritesh
    Gomes, Erica M.
    Bais, Anthony J.
    Lo, Agnes S. Y.
    Abedi, Mehrdad
    Davies, Robin A.
    Cabral, Howard J.
    Al-Homsi, A. Samer
    Cohen, Stephen I.
    [J]. PROSTATE, 2016, 76 (14) : 1257 - 1270
  • [19] microRNA cluster 106a∼363 is involved in T helper 17 cell differentiation
    Kaestle, Marc
    Bartel, Sabine
    Geillinger-Kaestle, Kerstin
    Irmler, Martin
    Beckers, Johannes
    Ryffel, Bernhard
    Eickelberg, Oliver
    Krauss-Etschmann, Susanne
    [J]. IMMUNOLOGY, 2017, 152 (03) : 402 - 413
  • [20] Epigenetic memory in induced pluripotent stem cells
    Kim, K.
    Doi, A.
    Wen, B.
    Ng, K.
    Zhao, R.
    Cahan, P.
    Kim, J.
    Aryee, M. J.
    Ji, H.
    Ehrlich, L. I. R.
    Yabuuchi, A.
    Takeuchi, A.
    Cunniff, K. C.
    Hongguang, H.
    Mckinney-Freeman, S.
    Naveiras, O.
    Yoon, T. J.
    Irizarry, R. A.
    Jung, N.
    Seita, J.
    Hanna, J.
    Murakami, P.
    Jaenisch, R.
    Weissleder, R.
    Orkin, S. H.
    Weissman, I. L.
    Feinberg, A. P.
    Daley, G. Q.
    [J]. NATURE, 2010, 467 (7313) : 285 - U60